Filing Details
CytomX Therapeutics, Inc. (NASDAQ:CTMX) filed a Form 8-K with the Securities and Exchange Commission on July 27, 2026, disclosing a material event.
8k filedNASDAQ:CTMX
CytomX Therapeutics, Inc. (CTMX) Reports Material Event to SEC
Filing Details CytomX Therapeutics, Inc. (NASDAQ:CTMX) filed a Form 8-K with the Securities and Exchange Commission on July 27, 2026, disclosing a material event. Market Context…
Market Context
CytomX Therapeutics, Inc.'s stock currently trades at $3.25 with a market capitalization of $686.8M. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for CytomX Therapeutics, Inc.'s stock.
All SEC filings for CytomX Therapeutics, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View CTMX Stock Page
Frequently Asked Questions
Where can I read CTMX's SEC filings?
Browse all filings on our CTMX SEC filings page.
What types of SEC filings does CytomX Therapeutics, Inc. file?
Public companies like CytomX Therapeutics, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.
